Latest Asx Companies News

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

TotalEnergies has lifted the force majeure on the $20 billion Mozambique LNG project, signaling a full restart after 4.5 years. RBR Group, uniquely positioned as the only ASX-listed company with direct exposure, stands to benefit from the surge in workforce and infrastructure demand.

Equity Story Group has raised $650,000 through a strategic convertible loan led by new Non-Executive Chair Alex Brinkmeyer, signaling a pivot into property funds management. The company also announced significant board changes, including the appointment of David Nolan as Managing Director.

Barton Gold Holdings has been added to the S&P Dow Jones ASX All Ordinaries Index, marking its rise among Australia's top 500 companies. The company is accelerating development of its South Australian gold projects, targeting significant production milestones by 2026.

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

The ASX has suspended trading in six companies starting 1 September 2025 due to late lodgement of mandatory periodic reports. The suspension may be lifted quickly if reports are filed promptly.

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.

ClearView Wealth Limited reported strong second-half growth in FY25, with underlying NPAT up 11% and life insurance margins rebounding. The company is poised for further expansion in FY26, backed by technology upgrades and strategic simplification.

InvestSMART Group has showcased its position as Australia’s leading direct-to-investor digital wealth platform, reporting $711 million in funds under management and highlighting its integrated ecosystem of low-cost funds, research, and tools.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.